Doxy.me vs Pfizer

Side-by-side comparison of AI visibility scores, market position, and capabilities

Pfizer leads in AI visibility (93 vs 39)
Doxy.me logo

Doxy.me

EmergingHealthcare

Telehealth

1M+ clinicians 150+ countries; 250K active providers; $50.2M revenue; acquired Telehealth.org/TeleMental Health Institute 2025; TIME HealthTech 2025; Ventures fund; telemedicine leader

AI VisibilityBeta
Overall Score
D39
Category Rank
#415 of 596
AI Consensus
81%
Trend
stable
Per Platform
ChatGPT
36
Perplexity
44
Gemini
39

About

Doxy.me was founded in 2013 by Brandon Welch in Hawaii with a mission to make telehealth accessible to every clinician and patient, regardless of technical sophistication or budget. The platform was built as a browser-based, zero-download video conferencing solution designed specifically for healthcare — requiring no app installation for patients and offering HIPAA-compliant video sessions out of the box. This simplicity-first approach drove grassroots adoption among solo practitioners and small clinics.\n\nDoxy.me's platform provides HIPAA-compliant video visits, virtual waiting rooms, patient intake forms, group rooms, and integrations with major EHR and practice management systems. Its free tier has been instrumental in driving adoption among independent clinicians who need compliant telehealth without enterprise procurement cycles. Premium tiers add advanced features including custom branding, staff accounts, and analytics. In 2025, Doxy.me acquired Telehealth.org and the TeleMental Health Institute, expanding its educational resources and professional training offerings.\n\nDoxy.me has grown to serve 1M+ clinicians across 150+ countries, with 250,000 active providers using the platform regularly. The company reported $50.2M in annual revenue and was recognized on TIME's HealthTech 2025 list. Its combination of clinical accessibility, global reach, and a freemium model that converts at scale positions Doxy.me as a foundational layer of the global telehealth infrastructure — particularly for solo and small-group practices that larger enterprise platforms overlook.

Full profile
Pfizer logo

Pfizer

LeaderHealthcare Tech

Enterprise

Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.

AI VisibilityBeta
Overall Score
A93
Category Rank
#1 of 596
AI Consensus
80%
Trend
up
Per Platform
ChatGPT
94
Perplexity
89
Gemini
94

About

Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.

Full profile

AI Visibility Head-to-Head

39
Overall Score
93
#415
Category Rank
#1
81
AI Consensus
80
stable
Trend
up
36
ChatGPT
94
44
Perplexity
89
39
Gemini
94
37
Claude
92
38
Grok
98

Key Details

Category
Telehealth
Enterprise
Tier
Emerging
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Doxy.me
Telehealth

Integrations

Only Pfizer
Pfizer is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.